Cathie's Ark Logo
Cerus Corp. Logo

ARKK Holdings of Cerus Corporation (CERS) - Updated Daily

Transplants and Blood Supply
Date
Direction
Shares
Fund Weight
Fund
March 20, 2023
BUY364.249k0.0136%ARKK
March 17, 2023
BUY131.947k0.0049%ARKK
March 16, 2023
BUY9.764k0.0004%ARKK
March 14, 2023
BUY130.490k0.0054%ARKK
March 13, 2023
BUY2.572k0.0001%ARKK

Key Statistics

⚖️Weighting🧢Market Cap
0.52%$495.55m
🏋🏿‍♂️Weight Rank In ARKK🌏Country
25🇺🇸United States
🏋️‍♀️Weight Rank Across All Funds💳ARK Estimated Cost Average
37$3.25
🎫ARK Ownership Percent
7.9%
Description
Cerus Corporation is dedicated solely to safeguarding the world's blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the US. Also in the US, the INTERCEPT Blood System for Cryoprecipitation is approved for production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex, a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency.
Website
www.cerus.com

Other ETFs That Hold CERS

Ticker
NameWeight
ARKGARK Genomic Revolution ETF0.96%
ARKKARK Innovation ETF0.54%

Research Notes and Commentary for CERS